[Indications, technics and results of argon laser photocoagulation of macular subretinal neovascularization]

Area of Science:

• Ophthalmology
• Retinal Diseases
• Medical Interventions

Background:

• Senile macular degeneration (SMD) involves new vessel growth that threatens central vision.
• Early detection and intervention are crucial for managing vision loss in SMD.

Purpose of the Study:

• To evaluate the efficacy of argon laser photocoagulation in treating subretinal new vessels in senile macular degeneration.
• To determine if the location of new vessels impacts treatment outcomes.

Main Methods:

• A randomized prospective trial involving 60 patients with SMD between 1977 and 1981.
• Patients were categorized into three groups based on new vessel distance from the fovea (100-200, 200-400, >400 microns).
• Subretinal new vessels visible on angiography and >100 microns from the foveola were treated with argon laser; control groups received no treatment.

Main Results:

• Argon laser treatment demonstrated a statistically significant effect (p<0.01) on stabilizing or improving visual acuity compared to the non-treated group after at least one year of follow-up.
• No significant difference in treatment efficacy was found across the three groups based on new vessel location.
• In cases of treatment failure, final visual acuity did not differ between treated and non-treated patients.

Conclusions:

• Argon laser photocoagulation is an effective treatment for stabilizing or improving visual acuity in senile macular degeneration patients with specific types of new vessel growth.
• The location of new vessels relative to the fovea did not influence the overall effectiveness of the argon laser treatment.
• While effective in some cases, treatment failure did not result in worse outcomes compared to non-intervention.